TY  - JOUR
AU  - Garcia-Donas, Jesus
AU  - Esteban, Emilio
AU  - Leandro-García, Luis Javier
AU  - Castellano, Daniel E
AU  - González del Alba, Aranzazu
AU  - Climent, Miguel Angel
AU  - Arranz, José Angel
AU  - Gallardo, Enrique
AU  - Puente, Javier
AU  - Bellmunt, Joaquim
AU  - Mellado, Begoña
AU  - Martínez, Esther
AU  - Moreno, Fernando
AU  - Font, Albert
AU  - Robledo Batanero, Mercedes
AU  - Rodriguez Antona, Cristina
PY  - 2011
DO  - 10.1016/S1470-2045(11)70266-2
UR  - http://hdl.handle.net/20.500.12105/17496
AB  - BACKGROUNDSunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell carcinoma, but some patients do not respond or need dose reductions due to toxicity. Because there are no validated molecular predictors of response or toxicity to...
LA  - eng
PB  - Elsevier
KW  - Polymorphism, Single Nucleotide
KW  - Aged
KW  - Antineoplastic Agents
KW  - Carcinoma, Renal Cell
KW  - Cytochrome P-450 CYP3A
KW  - Disease-Free Survival
KW  - Female
KW  - Gene Frequency
KW  - Genetic Predisposition to Disease
KW  - Heterozygote
KW  - Homozygote
KW  - Humans
KW  - Indoles
KW  - Kaplan-Meier Estimate
KW  - Kidney Neoplasms
KW  - Logistic Models
KW  - Male
KW  - Middle Aged
KW  - Patient Selection
KW  - Phenotype
KW  - Precision Medicine
KW  - Predictive Value of Tests
KW  - Proportional Hazards Models
KW  - Prospective Studies
KW  - Protein Kinase Inhibitors
KW  - Pyrroles
KW  - Risk Assessment
KW  - Risk Factors
KW  - Spain
KW  - Sunitinib
KW  - Time Factors
KW  - Treatment Outcome
KW  - Vascular Endothelial Growth Factor Receptor-3
TI  - Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
TY  - journal article
ER  -